16 July 2020
HealthDay Reports: Moderna COVID-19 Vaccine 'Promising' After Early Trial
Genetically derived from the virus, the mRNA vaccine essentially mimics a natural COVID-19 infection, tricking the body into producing antibodies that hopefully will protect against future infections.
Moderna COVID-19 Vaccine 'Promising' After Early Trial
TUESDAY, July 14, 2020 (HealthDay News) -- A leading COVID-19 vaccine contender has passed its early safety trial with flying colors.
The vaccine, created by Moderna, produced an immune response in all 45 healthy participants who received two shots 28 days apart, according to findings reported July 14 in the New England Journal of Medicine.
The vaccine (named mRNA-1273 for now) uses messenger RNA, or mRNA, to trigger an immune response to the COVID-19 coronavirus in patients.